These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39300963)

  • 21. Real-world prospective observational single-centre study: Hybrid closed loop improves HbA1c, time-in-range and quality of life for children, young people and their carers.
    Ng SM; Katkat N; Day H; Hubbard R; Quinn M; Finnigan L
    Diabet Med; 2022 Jul; 39(7):e14863. PubMed ID: 35488481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm.
    Buckingham BA; Forlenza GP; Pinsker JE; Christiansen MP; Wadwa RP; Schneider J; Peyser TA; Dassau E; Lee JB; O'Connor J; Layne JE; Ly TT
    Diabetes Technol Ther; 2018 Apr; 20(4):257-262. PubMed ID: 29431513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes.
    Polonsky WH; Fisher L; Hessler D; Edelman SV
    Diabetes Technol Ther; 2015 Nov; 17(11):773-9. PubMed ID: 26167948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged Use of an Automated Insulin Delivery System Improves Sleep in Long-Standing Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia.
    Malone SK; Matus AM; Flatt AJ; Peleckis AJ; Grunin L; Yu G; Jang S; Weimer J; Lee I; Rickels MR; Goel N
    J Diabetes Sci Technol; 2024 Nov; 18(6):1416-1423. PubMed ID: 37449426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.
    Wheeler BJ; Collyns OJ; Meier RA; Betts ZL; Frampton C; Frewen CM; Galland B; Hewapathirana NM; Jones SD; Chan DSH; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; de Bock MI
    Acta Diabetol; 2022 Jan; 59(1):31-37. PubMed ID: 34453208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-source automated insulin delivery systems (OS-AIDs) in a pediatric population with type 1 diabetes in a real-life setting: the AWeSoMe study group experience.
    Nir J; Rachmiel M; Fraser A; Lebenthal Y; Brener A; Pinhas-Hamiel O; Haim A; Stern E; Levek N; Ben-Ari T; Landau Z
    Endocrine; 2023 Aug; 81(2):262-269. PubMed ID: 37222881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management.
    Adams RN; Tanenbaum ML; Hanes SJ; Ambrosino JM; Ly TT; Maahs DM; Naranjo D; Walders-Abramson N; Weinzimer SA; Buckingham BA; Hood KK
    Diabetes Technol Ther; 2018 Oct; 20(10):648-653. PubMed ID: 30239219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range.
    Pulkkinen MA; Varimo TJ; Hakonen ET; Hero MT; Miettinen PJ; Tuomaala AK
    Diabetes Obes Metab; 2024 Jun; 26(6):2431-2438. PubMed ID: 38514384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial.
    Sherr JL; Bode BW; Forlenza GP; Laffel LM; Schoelwer MJ; Buckingham BA; Criego AB; DeSalvo DJ; MacLeish SA; Hansen DW; Ly TT; ; Sherr JL; Weyman K; Tichy E; VanName M; Brei M; Zgorski M; Steffen A; Carria L; Bode BW; Busby A; Forlenza GP; Wadwa RP; Slover R; Cobry E; Messer L; Laffel LM; Isganaitis E; Ambler-Osborn L; Freiner E; Turcotte C; Volkening L; Schoelwer M; Brown SA; Krauthause K; Emory E; Oliveri M; Buckingham BA; Ekhlaspour L; Kingman R; Criego AB; Schwartz BL; Gandrud LM; Grieme A; Hyatt J; DeSalvo DJ; McKay S; DeLaO K; Villegas C; MacLeish SA; Wood JR; Kaminski BA; Casey T; Campbell W; Behm K; Adams R; Hansen DW; Stone SL; Bzdick S; Bulger J; Agostini L; Doolittle S; Kivilaid K; Kleve K; Ly TT; Dumais B; Vienneau T; Huyett LM; Lee JB; O'Connor J; Benjamin E
    Diabetes Care; 2022 Aug; 45(8):1907-1910. PubMed ID: 35678724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
    Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
    Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes.
    Forlenza GP; Buckingham BA; Christiansen MP; Wadwa RP; Peyser TA; Lee JB; O'Connor J; Dassau E; Huyett LM; Layne JE; Ly TT
    Diabetes Technol Ther; 2019 May; 21(5):265-272. PubMed ID: 30925077
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study.
    Liarakos AL; Hasan N; Crabtree TSJ; Leelarathna L; Hammond P; Hussain S; Haq M; Aslam A; Gatdula E; Gibb FW; Lumb A; Bull K; Chinnasamy E; Carrieri G; Williams DM; Choudhary P; Ryder REJ; Wilmot EG
    Diabetes Res Clin Pract; 2024 Mar; 209():111597. PubMed ID: 38417535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion.
    Layne JE; Parkin CG; Zisser H
    J Diabetes Sci Technol; 2016 Sep; 10(5):1130-5. PubMed ID: 27290737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes.
    Marks BE; Meighan S; Zehra A; Douvas JL; Rearson A; Suresh R; Brown EA; Wolf RM
    Diabetes Technol Ther; 2023 Nov; 25(11):782-789. PubMed ID: 37646634
    [No Abstract]   [Full Text] [Related]  

  • 35. First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes.
    Forlenza GP; Buckingham BA; Brown SA; Bode BW; Levy CJ; Criego AB; Wadwa RP; Cobry EC; Slover RJ; Messer LH; Berget C; McCoy S; Ekhlaspour L; Kingman RS; Voelmle MK; Boyd J; O'Malley G; Grieme A; Kivilaid K; Kleve K; Dumais B; Vienneau T; Huyett LM; Lee JB; O'Connor J; Benjamin E; Ly TT
    Diabetes Technol Ther; 2021 Jun; 23(6):410-424. PubMed ID: 33325779
    [No Abstract]   [Full Text] [Related]  

  • 36. Psychosocial Effects of the Loop Open-Source Automated Insulin Delivery System.
    Wong JJ; Hood KK; Hanes SJ; Lal RA; Naranjo D
    J Diabetes Sci Technol; 2023 Nov; 17(6):1440-1447. PubMed ID: 35771004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life.
    McMahon SK; Airey FL; Marangou DA; McElwee KJ; Carne CL; Clarey AJ; Davis EA; Jones TW
    Diabet Med; 2005 Jan; 22(1):92-6. PubMed ID: 15606698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology.
    Hood KK; Schneider-Utaka AK; Reed ZW; Buckingham BA; Cobry E; DeBoer MD; Ekhlaspour L; Schoelwer M; Paul Wadwa R; Lum J; Kollman C; Beck RW; Breton MD;
    Diabetes Res Clin Pract; 2024 Feb; 208():111114. PubMed ID: 38278493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why #WeAreNotWaiting-Motivations and Self-Reported Outcomes Among Users of Open-source Automated Insulin Delivery Systems: Multinational Survey.
    Braune K; Gajewska KA; Thieffry A; Lewis DM; Froment T; O'Donnell S; Speight J; Hendrieckx C; Schipp J; Skinner T; Langstrup H; Tappe A; Raile K; Cleal B
    J Med Internet Res; 2021 Jun; 23(6):e25409. PubMed ID: 34096874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
    Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
    Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.